Cefpodoxime proxetil

Edina Avdic, Pharm.D., BCPS, Paul A. Pham, Pharm.D.
Cefpodoxime proxetil is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

MonkeypoxMonkeypox

Coronavirus COVID-19 (SARS-CoV-2)Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 PandemicSuicide Risk in the COVID-19 Pandemic

Moderna COVID-19 VaccineModerna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 VaccineJohnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Upper respiratory tract infections including acute otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis (AECB), and acute maxillary sinusitis
  • Acute uncomplicated urethral and cervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended by CDC) [3]
  • Uncomplicated skin and skin-structure infections S. aureus (MSSA) or S. pyogenes.
  • Uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilis, or S. saprophyticus.
  • Community-acquired pneumonia (CAP) caused by S. pneumoniae or H. influenzae

NON-FDA APPROVED USES

  • Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
  • Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
    • IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

  • Upper respiratory tract infections including acute otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis (AECB), and acute maxillary sinusitis
  • Acute uncomplicated urethral and cervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended by CDC) [3]
  • Uncomplicated skin and skin-structure infections S. aureus (MSSA) or S. pyogenes.
  • Uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilis, or S. saprophyticus.
  • Community-acquired pneumonia (CAP) caused by S. pneumoniae or H. influenzae

NON-FDA APPROVED USES

  • Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
  • Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
    • IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2022 Unbound Medicine, Inc. All rights reserved